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Abstract
Ethanolamine phosphoglycerol (EPG) is a protein modification attached exclusively to eukaryotic elongation factor 1A
(eEF1A). In mammals and plants, EPG is linked to conserved glutamate residues located in eEF1A domains II and III, whereas
in the unicellular eukaryote Trypanosoma brucei, only domain III is modified by a single EPG. A biosynthetic precursor of EPG
and structural requirements for EPG attachment to T. brucei eEF1A have been reported, but nothing is known about the EPG
modifying enzyme(s). By expressing human eEF1A in T. brucei, we now show that EPG attachment to eEF1A is evolutionarily
conserved between T. brucei and Homo sapiens. In contrast, S. cerevisiae eEF1A, which has been shown to lack EPG is not
modified in T. brucei. Furthermore, we show that eEF1A cannot functionally complement across species when using T. brucei
and S. cerevisiae as model organisms. However, functional complementation in yeast can be obtained using eEF1A chimera
containing domains II or III from other species. In contrast, yeast domain I is strictly required for functional complementation
in S. cerevisiae.
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Introduction
Eukaryotic translation elongation factor 1A (eEF1A) is a G-
protein which delivers aminoacyl-tRNAs (aa-tRNAs) to the
ribosomal A-site and allows for proper codon-anticodon mediated
deciphering of the genetic code. This reaction requires hydrolysis
of GTP to GDP and is assisted by eEF1B, a guanine nucleotide
exchange factor that regenerates GTP-bound eEF1A and in S.
cerevisiae consists of two subunits, eEF1Balpha which interacts
directly with eEF1A and eEF1Bgamma. A third subunit,
eEF1Bdelta, which also binds to eEF1A has been identified in
other organisms such as Artemia salina, rabbit and human fetal cells
(for a recent review describing eEF1 complexes, see [1]). The
primary structure of eEF1A is highly conserved among all
eukaryotes and prokaryotes (for which it is termed EF-Tu). The
crystal structure of yeast eEF1A has been elucidated, it consists of
three domains termed I, II and III [2,3]. Whereas domain I binds
guanine nucleotides, domains II and III are involved in the
binding of aminoacyl-tRNAs [2] and eEF1Balpha binds in the
hydrophobic pocket between domains I and II [3].
Being one of the most abundant proteins in eukaryotes (up to
5% of total cytosolic protein), several other functions besides its
canonical role in translation elongation have been assigned to
eEF1A (reviewed by [4]). Several covalent modifications such as
phosphorylation [5,6], lysine methylation [7,8] and carboxy
terminal methyl-esterification [9] have been reported to influence
eEF1A’s biological activity. Furthermore, eEF1A is uniquely
modified by ethanolamine phosphoglycerol (EPG) which is
attached to conserved glutamic acid residues in domains II and
III of mammalian and plant eEF1A [10,11,12]. In the parasitic
protozoan T. brucei, only domain III of eEF1A is EPG-modified
(residue E362) despite the presence of a second potential EPG
modification site in domain II (residue E289) [13]. Previous studies
using T. brucei as a model organism have shown that the
ethanolamine moiety in EPG originates from the phospholipid
phosphatidylethanolamine [13]. Moreover, E362 in T. brucei
eEF1A is strictly required for attachment of EPG, indicating that
the enzyme-mediated attachment of EPG (or its precursor
molecule) is highly specific for glutamic acid at this position
[14]. Surprisingly, T. brucei parasites expressing EPG-deficient
eEF1A show no detectable growth defect demonstrating that, at
least in cell culture, EPG attachment is not essential for eEF1A
function in T. brucei [15]. Remarkably - and despite structural
conservation of the glutamic acid residue in domain III (residue
E372) - S. cerevisiae eEF1A may lack EPG: analysis of the peptide
containing the postulated EPG attachment site by amino acid
sequencing showed no evidence for the presence of EPG-modified
glutamate [16]. We now confirm this observation using mass
spectrometry. In addition, we show that in contrast to human
eEF1A, S. cerevisiae eEF1A is not EPG-modified in T. brucei.
Furthermore, we found that despite highly conserved protein
sequences and similar predicted 3D-structures of yeast, T. brucei
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e42338
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
14
93
0 
| 
do
wn
lo
ad
ed
: 
8.
5.
20
16
and mammalian eEF1A, orthologs cannot replace the endogenous
protein. However, using plasmid shuffling techniques in S.
cerevisiae, we were able to show that inter-species chimeric forms
of eEF1A are able to functionally complement in vivo.
Methods
Materials
Unless otherwise specified, all reagents were of analytical grade
and were from Merck (Darmstadt, Germany), Sigma-Aldrich
(Buchs, Switzerland) or ICN Biomedicals (Ta¨gerig, Switzerland).
DNA polymerase was obtained from Invitrogen (Basel, Switzer-
land). Restriction enzymes were purchased from Thermo Scien-
tific (St. Leon-Rot, Germany) or New England Biolabs (Ipswich,
MA). [1-3H]ethan-1-ol-2-amine hydrochloride ([3H]Etn, 60 Ci
mmol21) was purchased from American Radiolabeled Chemicals
Inc. (St. Louis, MO). Kodak MBX films were from Kodak SA
(Lausanne, Switzerland).
Generation of Expression Plasmids for Studies in T. Brucei
Plasmids for constitutive expression were derived from the
trypanosome expression vector pCorleone [17]. The open reading
frames (ORFs) of H. sapiens eEF1A (accession number
NM_001402, position 64-1452, GenBank) and S. cerevisiae eEF1A
(YPR080W, Saccharomyces Genome Database) were amplified
using the primer pairs HA-1402f/1402r and HA-080Wf/080Wr,
respectively (Table S1a), and subcloned between the XhoI and
BamHI sites of pBluescript. Afterwards, the HindIII sites of both
ORFs were destroyed using the QuikChangeH Site-Directed
Mutagenesis kit (Stratagene, Basel, Switzerland) and primer pairs
Hs1402-895Af/Hs1402-895Ar and ScTEF1-411Ef/ScTEF1-
411Er (Table S1a), respectively. Finally, the mutated ORFs were
cloned between the HindIII and BamHI sites of pCorleone. The
resulting vectors were used as template for the amplification of the
appropriate ORFs lacking the HA-tags using primer pairs 1402f/
1402r for H. sapiens eEF1A and 080Wf/080Wr for S. cerevisiae
eEF1A. For conditional expression, PCR products were cloned
between BamHI and HindIII restriction sites of pALC14 vector
carrying a blasticidin resistance gene. The synthesis of the
Leishmania major eEF1A ORF (accession number LmjF17.0080,
TriTrypDB) was done using primer pair Lm0080f/Lm0080r
(Table S1a). The PCR product was cloned into pALC14 vector, as
described above. Prior to transfection into T. brucei, all vectors
were linearized with NotI and SalI.
Cell Culture and Transfection into T. Brucei
T. brucei procyclic form (PCF) Dprocyclin#1 (EP/GPEET null
mutant) [18] and the derived cell lines were grown at 27uC in
DTM supplemented with 15% heat-inactivated fetal bovine serum
(FBS) (Invitrogen, Basel, Switzerland) [19]. The T. brucei PCF
‘‘C5’’ RNAi cell line against T. brucei eEF1A [20] derived from
strain 29-13 [21] was cultured at 27uC in SDM79 supplemented
with 15% FBS and 25 mg/ml hygromycin, 15 mg/ml G-418 and
2 mg/ml puromycin. The T. brucei strain C5-E conditionally
expressing an ectopic copy of T. brucei eEF1A [20] was cultured in
the same medium with additional 10 mg ml21 blasticidin S HCl
(Invitrogen). Trypanosomes were stable transfected using 10–
15 mg of linearized plasmid DNA and selected with 10 mg ml21
blasticidin S HCl. Transfection, selection with antibiotics and
cloning were performed as described elsewhere [22]. RNA
interference (RNAi) to down-regulate endogenous eEF1A expres-
sion and conditional expression of eEF1A proteins in the C5 cell
line were induced by the addition of 1 mg/ml tetracycline [23].
In vivo Labeling, Extraction and Immunoprecipitation
Trypanosomes were labeled during exponential growth
(0.520.86107 cells ml21) with 1 mCi ml21 [3H]Etn for 18 h
[24] and extracted as described previously [15]. The cell lysate was
homogenized by passing three times through a 27-gauge needle
and centrifuged at 169000 g for 30 min. Subsequently, anti-HA
Affinity Matrix (Roche Diagnostics) was added to the supernatant
and incubated on a rotating device overnight at 4uC. The beads
were spun down and washed three times with lysis buffer as
described [15]. Tagged proteins were removed form the matrix by
boiling in electrophoresis sample buffer.
SDS-polyacrylamide Gel Electrophoresis (SDS-PAGE) and
Immunoblotting
Extracted proteins were separated by glycine-SDS-PAGE under
reducing conditions using 12% polyacrylamide gels. For fluorog-
raphy of 3H-labeled proteins, gels were fixed (10% methanol, 7%
acetic acid), soaked in Amplify (GE Healthcare), dried, and
exposed to Kodak MBX films at 270uC. Semi-dry blotting was
performed as previously described [15]. Mouse monoclonal
antibody against hemagglutinin (a-HA; Covance, Berkeley, CA)
was used at a dilution of 1:3000 and was detected with secondary
rabbit anti-mouse IgG antibody conjugated to horseradish
peroxidase (Dako, Baar, Switzerland) at a dilution of 1:5000,
followed by enhanced chemiluminescence (Pierce, Lausanne,
Switzerland).
Mass Spectrometry
Immunoprecipitated HA-eEF1A proteins were analyzed by
SDS-PAGE and immunoblotting as described above. After
staining with Coomassie Brilliant Blue, HA-eEF1A proteins were
cut out, cut into small pieces and exposed to on-membrane
reductive alkylation and trypsin digestion [25]. The tryptic
peptides were analyzed by liquid chromatography tandem mass
spectrometry (nano-LC-MS/MS) as described previously [15].
Carboxy-terminally His6x-tagged ScEF1A was purified from yeast
cell extracts essentially as described [26]. ScEF1AHis6x was
transferred to a PVDF-membrane (BIO-RAD) and mass spectro-
metric analysis was carried out after on-membrane tryptic
digestion. Tryptic peptides were analyzed by liquid mass
spectrometry (nano-LC-MS/MS) as described previously.
Northern Blot Analysis
Total RNA for Northern blotting was isolated using a SV Total
RNA Isolation System (Promega, Madison, WI) and 10 mg of the
total RNA was separated on formaldehyde-agarose gels (1%
agarose, 2% formaldehyde in 20 mM 3-(N-morpholino)propane-
sulfonic acid). To control for equal loading, rRNA was visualized
by ethidium bromide staining. Afterwards, RNA was transferred
from the gel to positively charged nylon membrane, Hybond-N+
(GE Healthcare, Glattbrugg, Switzerland). Detection of polycis-
tronic TbEF1A mRNA using a 32P-labeled probe made by
random priming of the PCR product of TbEF1A intergenic region
1, subsequent hybridization and analysis by autoradiography using
Bio-Max MS film and a TransScreen-HE intensifying screen was
performed as described previously [20].
Reverse Transcription PCR Analysis
To demonstrate the presence of transcripts of Hs-EF1A, Sc-
EF1A, Lm-EF1A, and Tb-EF1A reverse transcription-PCR (RT-
PCR) was performed. Total RNA was extracted from trypano-
somes 72 h after induction with tetracycline. Complementary
DNA (cDNA) was produced from single-strand RNA according to
eEF1A Domain I Is Required for Complementation
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the manufacturer’s guidelines (SuperScriptH II Reverse Transcrip-
tase and Oligo(dT)20 Primer, Invitrogen) using 1 mg of extracted
total RNA. Amplification of cDNA was done in 30 cycles using
primer pairs (Table S1b), specific for the eEF1A ORFs in S.
cerevisiae (ScTEF1_RT_f/ScTEF1_RT_r), H. sapiens
(HsTEF1_RT_f/HsTEF1_RT_r), L. major (Lm080_RT (f)/
Lm080_RT (r)) or T. brucei (TbTEF1_RT_f/TbTEF1_RT_r;
accession number Tb927.10.2100, TriTrypDB). Total RNA
extract was used as a negative control and PCR products were
analyzed by electrophoresis using 0.8% agarose gel.
In Silico Analysis
To build three-dimensional models of eEF1A proteins, pdb
formats were generated as previously described [27,28,29] or
directly downloaded from Protein Database (www.pdb.org).
Subsequently structural models have been drawn with PyMOL
Molecular Graphics System (DeLano WL).
Cloning, Plasmids and Strains for in vivo
Complementation Assays in S. Cerevisiae
Yeast strains as well as plasmids used and generated in this study
are listed in the Supplemental Information (Tables S3, S4). eEF1A
genes from T. brucei, L. major, H. sapiens were PCR amplified from
plasmids pRS314_HA-TbTEF1 (E. coli strain #1873) and
pMC4_HsTEF1 (E. coli strain #2056), pMC4_LmTEF1 (E. coli
strain #2057) respectively. C. albicans eEF1A (CaTEF1) and A.
thaliana eEF1A (AtTEF1) domain III were PCR amplified from a
C. albicans cDNA library (a gift from D. Sanglard, University of
Lausanne) and an A. thaliana cDNA library (a gift from D. Rentsch,
University of Bern). 59BamHI and 39SpeI restriction sites – or
59BamHI and 39SacI restriction sites for CaTEF1– flanking the
ends of ORFs were introduced with the help of oligonucleotide
primers during PCR (Table S2a). Amino- and carboxy-terminally
His6x-tagged forms of ScTEF1 were also obtained by PCR, using
primers carrying tag sequences (Table S2a). Chimeric forms of
eEF1A were obtained by exchanging single domains of eEF1A
from different eukaryotic sources followed by ligation with yeast
eEF1A domains. Domain exchange was achieved by introduction
of unique restriction sites at highly conserved amino acid sequence
motifs, as determined by multiple sequence alignments using
ClustalW2 algorithm. Between eEF1A domains I and II, a SpeI
restriction site was introduced by site-directed mutagenesis and a
BamHI restriction site between domain II and III (Table S2b).
Constructs were verified by sequencing and transformed into the
conditional lethal yeast strain TKY102 (kindly provided by T. G.
Kinzy, University of Medicine and Dentistry of New Jersey)
carrying deletions of TEF1 and TEF2 (both genes encoding
eEF1A) and the plasmid ,TEF2_URA3. (for genotypic details,
see Table S4). After transformation, plasmid shuffling was carried
out on 0.5 mg/mL 5-FOA (5-fluoro orotic acid) plates to
counterselect for the loss of ,TEF2_URA3.. Media, yeast and
E. coli cell transformations were performed according to standard
procedures.
Phenotypic Characterization of Mutant eEF1A Forms in S.
Cerevisiae
All constructs were transformed into the conditional lethal strain
TKY102. Transformants were subjected to plasmid shuffling and
analyzed for growth on 0.5 mg/mL 5-FOA-containing plates by
incubating them for 3–8 days at 25uC or 30uC. Viable mutants
were harvested from 5-FOA and grown in 2–5 mL overnight
cultures of YPD at 30uC. Next day, cells were diluted to a starting
OD600 of 0.2–0.5 and grown until an OD600 of 1–1.2 was reached.
Cell samples were brought to an OD600 of 1 for spotting dilutions.
Plates were incubated at 25uC, 30uC or 35uC for 2–3 days.
Results
HsEF1A, but not ScEF1A, is Modified with EPG in T. Brucei
eEF1A proteins from H. sapiens, T. brucei and S. cerevisiae show
high amino acid sequence homology (Fig. S1) and the predicted
3D structure of H. sapiens and T. brucei eEF1A closely match the
three dimensional structure of S. cerevisiae eEF1A determined by X-
ray crystallography [2,3]. All structures predict the EPG attach-
ment site of domain III to be at the surface of a b-sheet (Fig. 1A).
Based on the (predicted) conservation of tertiary structures and
EPG modification sites, we postulated that when expressed in T.
brucei parasites, eEF1A of S. cerevisiae and H. sapiens would become
modified by EPG by the trypanosome enzyme(s).
To test this hypothesis, HA-tagged H. sapiens eEF1A (HA-
HsEF1A) and HA-tagged S. cerevisiae eEF1A (HA-ScEF1A) were
expressed from ectopic copies in the EP/GPEET locus of T. brucei
Dprocyclin#1 cells. Immunoblotting experiments demonstrated
that HA-tagged eEF1A from both organisms were expressed in T.
brucei and could be detected using a-HA antibodies (Fig. 1B, upper
panels). Labeling of these parasites with [3H]Etn revealed a single
radioactive band at 49 kDa after SDS-PAGE and fluorography,
representing EPG-modified eEF1A (Fig. 1B, lower panels, lanes L)
(see also [13,15]). To distinguish between [3H]-labeled endoge-
nous and HA-tagged eEF1A, parasite lysates were incubated with
anti-HA antibody and the immunoprecipates were analyzed by
SDS-PAGE and fluorography. The results show that while
immunoprecipitated HA-HsEF1A was labeled with tritium, no
radioactivity was recovered in HA-ScEF1A, indicating that human
but not yeast eEF1A was modified with EPG (Fig. 1B, lower
panels, lanes IP).
Mass spectrometry analysis of eEF1A proteins expressed in T.
brucei confirmed the results obtained from in vivo labeling
experiments. HA-HsEF1A revealed a tryptic fragment with m/z
804.386 and 402.697, representing the [M+H]+ and [M+2H]2+
ions of the modified peptide FAE*LK (with E* representing the
potential EPG attachment site E374). Manual interpretation of the
fragment spectra of both parental ions identified E374 as the site of
EPG attachment (results not shown). In contrast, analysis of the
HA-ScEF1A revealed a tryptic fragment with m/z 893.467 and
447.237, representing the [M+H]+ and [M+2H]2+ ions of the
unmodified heptapeptide FDE*LLEK (with E* representing the
potential EPG attachment site E372) (Table 1; see also [15]). MS/
MS analysis of the parental ion at m/z 447.237 confirmed the
absence of EPG (results not shown). The tryptic peptides
SVEMHHEALSE*ALPGDNVGFNV (with E* representing
E301 in HA-HsEF1A) and SVEMHHEQ-
LE*QGVPGDNVGFNVK (with E* representing E298 in HA-
ScEF1A) in domains II of the respective proteins were not
modified with EPG either (see Table 1 for corresponding [M+H]+
and [M+2H]2+ ions). Together, these results demonstrate that
despite the structural conservation of eEF1A proteins from
different organisms, only HA-HsEF1A but not HA-ScEF1A could
serve as substrate for EPG attachment in T. brucei.
To re-visit an earlier report showing that EPG is absent in S.
cerevisiae eEF1A [16], we expressed a His6x-tagged form of eEF1A
in a S. cerevisiae lacking endogenous eEF1A and analyzed the
immunoprecipitated protein by LC-MS/MS. The results gained
on the tryptic peptides FDELLEK and FDELLEKNDR showed
that residue E372 was not modified either (Table 1). We conclude
that S. cerevisiae eEF1A does not become EPG-modified in any of
both tested systems (yeasts and trypanosomes).
eEF1A Domain I Is Required for Complementation
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The Growth Defect of eEF1A-depleted T. Brucei cannot
be Rescued by eEF1A Orthologs
Based on the above mentioned observations, we decided to
investigate if HsEF1A and ScEF1A are able to complement T.
brucei eEF1A (TbEF1A) function. In a previous study, we
generated a tetracycline-inducible T. brucei cell line (named C5)
in which expression of TbEF1A was ablated using RNAi, resulting
in growth arrest of the parasites [20]. In the same work, we showed
that growth could be fully restored by expressing an inducible
ectopic copy of TbEF1A. The same approach was used in the
present work to introduce ectopic inducible copies of wild-type
HsEF1A and ScEF1A into the C5 RNAi cell line and to study
their possible functional complementation in T. brucei. The
addition of tetracycline to the culture medium allowed us to
simultanously down-regulate endogenous TbEF1A and induce
expression of HsEF1A or ScEF1A. The results showed that neither
HsEF1A nor ScEF1A were able to complement the growth defect
of TbEF1A-depleted T. brucei, whereas TbEF1A fully restored
growth (Fig. 2A, see also [20]). Complementation of TbEF1A was
further studied by conditionally expressing eEF1A from L. major
(LmEF1A) in the C5 cell line, which is highly homologous to
TbEF1A, differing in only 25 amino acids (Fig. S1). However, no
complementation was observed with LmEF1A (Fig. 2A).
Northern blot analyses using a probe against TbEF1A
intergenic region 1 confirmed that in all cell lines transcription
of endogenous TbEF1A was down-regulated (Fig. 2B, upper
panels). To demonstrate that transcripts of the various eEF1A
orthologs were made upon tetracycline induction, we performed
RT-PCR using the same RNA samples used for Northern Blot
analysis in combination with primer pairs allowing for discrimi-
nation between mRNA derived from endogenous TbEF1A versus
that from eEF1A orthologs (Table S1b). RT-PCR analysis
confirmed the absence of endogenous TbEF1A mRNA in the
cell lines expressing HsEF1A, ScEF1A and LmEF1A, respectively
(Fig. 2C, lanes 5, 9, 13). In addition, RT-PCR confirmed
expression of ectopic TbEF1A, HsEF1A, ScEF1A and LmEF1A
mRNA, i.e. the corresponding transcripts were detected after 72 h
of induction (Fig. 2C, lanes 2, 6, 10, 14). Together, these results
demonstrate that eEF1A orthologs are unable to restore normal
growth of TbEF1A-depleted T. brucei in culture and fail to
complement the essential functions of TbEF1A.
eEF1A Orthologs Fail to Complement S. Cerevisiae eEF1A
Next, we decided to perform analogous complementation assays
for in vivo functionality in S. cerevisiae. For this purpose, we cloned
cDNAs encoding eEF1A-ORFs from T. brucei, H. sapiens, C. albicans
Figure 1. Expression and [3H]Etn-labeling of eEF1A orthologs in T. Brucei. (A) The predicted three-dimensional structures of eEF1A from T.
brucei (left), H. sapiens (middle) and the X-ray structure of S. cerevisiae (right) are illustrated to document structural similarities. The positions of the
glutamate residues representing potential EPG modification sites are indicated. The nomenclature of domains I, II, III is indicated for S. cerevisiae
eEF1A. (B) T. brucei Dprocyclin#1 expressing HA-tagged human (HA-HsEF1A) or yeast (HA-ScEF1A) eEF1A were incubated in the presence of [3H]Etn
for 18 h. Proteins in cell lysates (L) and in supernatants (SN), wash solutions (W) and the final pellet after immunoprecipitation using anti-HA antibody
(IP) were separated by SDS-PAGE and analyzed by immunoblotting using a-HA monoclonal antibody (a-HA; upper panels) or fluorography (lower
panels). Lanes contain extracts from 16107 (for L, SN and W) or 1.86108 cell equivalents (for IP). Molecular mass markers (kDA) are indicated.
doi:10.1371/journal.pone.0042338.g001
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and L. major into the yeast vector pRS314 under the control of the
yeast eEF1A promoter und transformed them into the conditional
lethal yeast strain TKY102, a conditionally lethal strain which
expresses the essential yeast eEF1A activity from a ,TEF2_UR-
A3.plasmid [30]. Subsequently, transformed cells were subjected
to the loss of the ,URA3.plasmid by plating them on 5-FOA. As
shown in Fig. 2D, amino- or carboxyterminal His6x-tagged forms
of ScEF1A were able to replace the endogenous wild-type eEF1A
gene copy by plasmid shuffling and allow for growth on 5-FOA.
However, none of eEF1A orthologs was able to replace yeast
eEF1A in TKY102 cells (Fig. 2D).
Inter-species Chimeric Forms of eEF1A
Since the results presented above demonstrate that full length
eEF1A cDNAs from H. sapiens, T. brucei, L. major or C. albicans
cannot complement for the loss of yeast or T. brucei eEF1A (Fig. 2),
inter-species chimeric eEF1A genes were generated and analyzed
in S. cerevisiae. Single domains of eEF1A from different eukaryotic
species were interchanged. Introduction of restriction sites at
highly conserved sequence motifs allowed for separation of single
eEF1A domains (Fig. 3A). The ‘‘…KIGGI…’’ amino acid motif
(residues 253–257 in ScEF1A) was mutagenized to introduce a
SpeI restriction site between domains I and II. It is located at the
first turn of the b sheet structure in domain II and is found in
eEF1A from T. brucei, H. sapiens and A. thaliana (Fig. 3A; Fig. S1).
This new restriction site creates a I254T/G255S mutation in
eEF1A. The ‘‘…KNDP…’’ amino acid motif (residues 328 to 331
in ScEF1A) is conserved among all studied eEF1A orthologs
(Fig. 3A; Fig. S1) and was mutagenized to introduce a BamHI
restriction site between domains II and III. This new restriction
site creates a N329K mutation in ScEF1A. Both mutations,
I254T/G255S and N329K were re-converted by site-directed
mutagenesis to the original eEF1A amino acid sequences following
construction of the chimera. All constructs presented in Fig. 3B
were transformed into the conditionally lethal yeast strain
TKY102.
After plasmid shuffling, constructs carrying a non yeast domain
III such as ScI_ScII_HsIII [construct 2] and ScI_ScII_TbIII
[construct 4] were found to complement yeast strain TKY102,
whereas constructs only carrying yeast domain III such as
TbI_TbII_ScIII [construct 5] and HsI_HsII_ScIII [construct 3]
did not complement, indicating that ScEF1A domain III may be
interchangeable (Fig. 3C). However, no growth on 5-FOA was
reported for ScI_ScII_AtIII [construct 6], neither at 25uC nor at
30uC.
As indicated, the point mutation created by introduction of an
artificial BamHI site (N329K mutation) had no effect on in vivo
functionality of ScI_ScII_HsIII [construct 2] and ScI_ScII_TbIII
[construct 4] chimeric forms in S. cerevisiae (Fig. 3C). Growth
studies on full media plates revealed that ScI_ScII_TbIII
[construct 4] with or without N329K mutation rendered a severe
slow growth phenotype, which was not observed for ScI_ScII_H-
sIII [construct 2] or ScI_ScII_HsIII [construct 2] N329K.
Additionally, ScI_ScII_TbIII [construct 4] also showed a temper-
ature sensitive growth phenotype (no growth at 35uC; Fig. 3D).
In addition, we observed that ScI_HsII_ScIII [construct 8] was
able to complement endogenous yeast eEF1A. Although the
amino acid sequence differs in only few residues from wild type
ScEF1A, the construct produced a temperature sensitive growth
phenotype (Fig. 3D). Interestingly, ScI_HsII_ScIII [construct 8]
eEF1A chimera carrying a I254T, G255S double mutation due to
introduction of the artificial SpeI restriction site was lethal
(Fig. 3C). Also, chimeric construct ScI_HsII_HsIII [construct
Table 1. Characteristic ions of the tryptic fragments of eEF1A proteins detected by mass spectrometry.
Protein Tryptic fragment [M+H]+ [M+H]2+ [M+H]3+ EPG
T. brucei EF1Aa FAE*IESK/FAEIESK 1020.465/823.420c 510.736/412.214d n.d. +
S. cerevisiae EF1Ab FDE*LLEK/FDELLEK 893.467 2/447.23 n.d. 2
FDE*LLEKNDR/FDELLEKNDR n.d. 2/639.820 2/426.883 2
FDE*LLEKNDRR/FDELLEKNDRR n.d. 2/717.862 2/478.91 2
SVEMHHEQLE*QGVPGDNVGFNVK/
SVEM(ox)HHEQLEQGVPGDNVGFNVK
n.d. 2/1275.609 (M(ox)/
1283.604)
2/850.741 (M(ox)/
856.071)
2
H. sapiens EF1Ab FAE*LK/FAELK 804.386/2 402.697/2 n.d. +
SVEMHHEALSE*ALPGDNVGFNV/SVEMHHEALSEALPGDNVGFNV n.d. 2/1240.595 (M(ox)/
1248.592)
2/827.398 (M(ox)/
832.73)
2
S. cerevisiae EF1AHis6x
c FDE*LLEK/FDELLEK n.d. 2/447.23 n.d. 2
FDE*LLEKNDR/FDELLEKNDR n.d. 2/639.820 2/426.882 2
SVEMHHEQLE*QGVPGDNVGFNVK/
SVEM(ox)HHEQLEQGVPGDNVGFNVK
n.d. 2/1275.605 (M(ox)/
1283.603)
2/850.741 (M(ox)/
856.07)
2
HA-eEF1A proteins expressed in T. brucei were purified, digested with trypsin and subjected to nano-LC-MS/MS as described in Materials and Methods. Purified carboxy-
terminally His6x-tagged S. cerevisiae eEF1A was treated prior to nano-LC-MS/MS the same way as for HA-tagged eEF1A proteins. Tryptic fragments containing the site of
potential EPG attachment E362, E298/E372, E301/E374 of domainII/domain III from T. brucei, S. cerevisiae and H. sapiens eEF1A, respectively (all marked with an asterisk)
are shown with their corresponding [M+H]+, [M+H]2+ and [M+H]3+ ions. The last column indicates the presence (+) or absence (2) of EPG modifications based on ion
data.
n.d., not detected.
2,not present.
Ox, oxidation.
a,described in [15].
b,expressed as HA-tagged protein in T. brucei.
c,expressed as His6x-tagged protein in S. cerevisiae.
d,the relative intensities of the [M+H]+ ions of the EPG-modified (m/z 1020.465) and unmodified (m/z 823.420) tryptic peptides suggest that .95% of T. brucei eEF1A is
modified with EPG (see [15]).
doi:10.1371/journal.pone.0042338.t001
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10], which carries human domains II and III, was not able to
complement for the loss of endogenous eEF1A.
Finally, all constructs lacking yeast domain I such as
HsI_ScII_ScIII [construct 11], HsI_ScII_HsIII [construct 9],
HsI_HsII_ScIII [construct 3] and TbI_TbII_ScIII [construct 5]
Figure 2. In vivo complementation assays in T. brucei and S. cerevisiae depleted for endogenous eEF1A. (A) T. brucei RNAi parasites
expressing ectopic copies of TbEF1A, HsEF1A, ScEF1A or LmEF1A were cultivated in the absence (2) or presence (+) of tetracycline (tet) for 7 days.
Each day, cultures were diluted to a cell density of 36106 cells/ml and incubated with fresh medium. Non-induced HsEF1A, ScEF1A and LmEF1A cell
lines showed the same growth curve as non-induced cell line TbEF1A: for simplicity, only the growth curve for TbEF1A is shown (see also [20]). (B)
Northern blots of total RNA extracted from parasites after 3 days of incubation in the absence (2) or presence (+) of tetracycline (tet) and hybridized
with 32P-labeled probes against the intergenic region 1 of T. brucei eEF1A (top); rRNA was used as a loading control (bottom). (C) RT-PCR analysis of
eEF1A transcripts. cDNA was synthesized from transcripts of T. brucei RNAi parasites cultured in the absence (2) or presence (+) of tetracycline for
72 h using primers specific for the different eEF1A orthologs (Table S1b). Lanes containing cDNA or total RNA (negative controls) are indicated. (D)
Complementation assays in S. cerevisiae strain TKY102 expressing as unique source endogenous eEF1A from a URA3-plasmid. Cells were transformed
with plasmids carrying genes encoding for different eEF1A orthologs. Upon transformation (upper panel), cells were incubated for several days on a
plate containing 5-fluoroorotic acid (5-FOA) which is toxic in the presence of the URA3 plasmid. Only transformants which were able to loose due to
mitotic segregation the URA3-plasmid grew on 5-FOA containing medium (lower panel). The numbers represent wild-type ScEF1A (1), HA-TbEF1A (2),
TbEF1A (3), LmEF1A (4), HsEF1A (5), vector pRS314 (6, negative control), CaEF1A (7), His6x-ScEF1A (8), and ScEF1A-His6x (9).
doi:10.1371/journal.pone.0042338.g002
Figure 3. Complementation of chimeric eEF1A in S. Cerevisiae. (A) Sequence alignment of conserved amino acid motifs separating domains I
and II (upper panel) and II and III (lower panel) of eEF1A from different sources. To generate chimeric constructs, synthetic SpeI (triangle) or BamHI
(arrow) cloning sites were introduced. (B) Schematic representation of chimeric constructs. Arrows and triangles indicate the positions of the cloning
sites which were removed by site-directed mutagenesis to reconstruct the original eEF1A sequences. Numbers in brackets correspond to clones
shown in Fig. 3C. (C) Complementation of S. cerevisiae strain TKY102 with chimeric eEF1A constructs. Upper panels: Yeast cells growing on plates
after transformation with different chimeric constructs. Middle and bottom panels: Counterselection for the loss of endogenous eEF1A on plates
containing 5-FOA at 25 or 30uC. Left panels: Complementation assays with chimeric constructs carrying cloning sites causing a N329K mutation in the
case of the artificial BamHI-site (separating domains II and III) or I254T/G255S mutations in the case of the artificial SpeI-site (separating domains I and
II). Right panels: complementation assays with chimeric constructs after reconstructing wild type eEF1A sequence motifs. (D) Growth properties of S.
cerevisiae complemented with chimeric eEF1A constructs. (1) positive control with yeast eEF1A; (2) Chimeric yeast constructs carrying human domain
III - without or with N329K mutation; (4) Chimeric yeast constructs carrying T. brucei domain III - without or with N329K mutation; (8) Chimeric yeast
eEF1A construct carrying humain domain II.
doi:10.1371/journal.pone.0042338.g003
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were not able to support growth of TKY102 on 5-FOA plates
(Fig. 3C, D).
Discussion
Our results using in vivo labeling and mass spectrometry
demonstrate that EPG is attached to E374 of HA-tagged HsEF1A
expressed in T. brucei procyclic forms in culture. The attachment
site corresponds to the same residue that is modified in HsEF1A in
mammalian cells [12] and is conserved in TbEF1A [13] and plants
[10]. In contrast, the second attachment site of HsEF1A, E301 was
not modified in T. brucei. Thus, the enzymatic machinery of T.
brucei EPG-modified HsEF1A the same way as endogenous
TbEF1A, which is modified in domain II but not in domain III
[15]. Since the enzymes involved in EPG attachment have not
been characterized so far, we can only hypothesize if there is one
phylogenetically ancient enzyme present in T. brucei, which later
during evolution developed the capacity to modify domain II of
eEF1A in mammalian and plant cells, or if two different EPG
modifying enzyme systems exists in these multicellular organisms.
Interestingly, S. cerevisiae represents so far the only eukaryote
lacking EPG modification of eEF1A ([16] and this work). It is not
known, if yeast eEF1A lacks EPG because the biosynthetic
pathway is deficient or if structure or sequence differences in yeast
eEF1A prevent EPG attachment. We now found that HA-tagged
S. cerevisiae eEF1A was not EPG-modified when expressed in T.
brucei. The lack of EPG attachment was surprising, since the 3D-
structure of yeast eEF1A closely matches that of T. brucei eEF1A
and the (potential) EPG modification site on the surface of a b-
sheet in domain III is conserved between yeast and T. brucei. In a
previous report we have shown that replacement of the primary
sequence around the EPG attachment site of T. brucei eEF1A
(FAE*IESK; with E* representing the EPG attachment site) by the
yeast sequence (FDE*LLEK; with E* representing the potential
EPG attachment site) didn’t affect EPG modification in T. brucei.
Thus, the different amino acid sequence around the EPG
attachment site of S. cerevisiae eEF1A per se did not prevent EPG
attachment [15].
Since EPG was only attached to human but not to yeast eEF1A
despite structural similarity, we decided to perform complemen-
tation assays in T. brucei in which the endogenous (T. brucei) eEF1A
is down-regulated by RNAi and the depletion phenotype is
dependent on the expression of an eEF1A homolog from related
(L. major) or unrelated organisms (H. sapiens, S. cerevisiae). The results
showed that none of the conditionally expressed eEF1A proteins
could rescue TbEF1A depletion in T. brucei. These findings were
confirmed in eEF1A-depleted S. cerevisiae cells, where none of the
expressed eEF1A proteins (T. brucei, H. sapiens, L. major, C. albicans)
could rescue the depletion phenotype. The lack of complemen-
tation cannot be due to missing EPG modifications as human
eEF1A is properly expressed and EPG-modified in T. brucei.
Furthermore, it has been recently shown that a mutated version of
T. brucei eEF1A lacking EPG is able to complement endogenous
eEF1A in cell cultures [20]. Although the primary sequences and
(predicted) three-dimensional structures of the different eEF1A
orthologs tested in this study are highly homologous, it should be
kept in mind that a single amino acid substitution may be sufficient
to cause lack of complementation across species, e.g. by impeding
proper interaction with partner proteins such as eEF1B, or by
interfering with other essential posttranslational modifications.
Furthermore, we cannot exclude that unequal codon usage among
species may be a cause for the lack of complementation of the
different eEF1A orthologs. Silent mutations can influence the
folding of a protein due to varying levels of isoacceptor tRNAs
affecting the velocity rate of translation elongation [31].
Together, these results demonstrate that the essential compo-
nent of protein translation eEF1A, despite high sequence
conservation and overall similarity in 3D-structure is unable to
functionally complement across species. Interestingly, functional
complementation across species has been reported for other
translation factors such as eIF4E [32] but not between all species
[33]. In addition, similar findings to those described here have
been reported for another essential translation factor, eIF4A, in
which orthologs from different sources could not support protein
synthesis either in vivo or in vitro in an eIF4A-depleted yeast cell
system [34,35] despite the fact that they share sequence elements
and function in large number of biochemical reactions ([36];
reviewed by [37]).
By constructing a series of inter-species eEF1A chimera and
expressing them in the conditionally lethal strain S. cerevisiae
TKY102, we found that the carboxy terminus of certain eEF1A
proteins (comprising domain II or domain III) can be exchanged
without loss of viability. Domain III from A. thaliana was not able
to complement in conjunction with yeast eEF1A domains I and II
as a chimeric construct. This came as a surprise, as plants are
assumed to be evolutionary closer related to yeast than human or
trypanosome genes and demonstrated that there are also
constraints to exchanging the essential domain III of yeast eEF1A.
In contrast, the amino terminus (comprising domain I) is
essential for function in S. cerevisiae. Similar findings have been
reported for eubacterial EFTu, where recombinant chimeric
elongation factor containing domain I of aEF1A from archea
Sulfolobus solfataricus and domains II and III from Escherichia coli EF-
Tu did not sustain poly(Phe) synthesis in either a S. solfataricus or a
E. coli assay system [38].
The essentiality of domain I may be explained as follows: (i)
Domain I is crucial for interactions with macromolecules involved
in the process of protein elongation such as ribosomal proteins and
other interaction partners like eEF1B. eEF1A is a well-known
member of the superfamily of GTPases and carries regions
essential for binding of GTP and the Mg2+ ion in domain I (switch
regions 1 and 2). The GTPase activity of eEF1A is affected by
ribosomes that trigger the hydrolysis of GTP in eukaryotes and
similarly, they enhance by more than100-fold the intrinsic GTPase
activity of EF-Tu in bacteria [39]. In addition, the dissociation of
GDP from eEF1A is accelerated by eEF1B (EFTs in bacteria) that
binds between domain I and domain II of eEF1A [40–41]. Upon
binding of eEF1B conformation changes of eEF1A i.e. in the
switch region 2 are induced and affect the nucleotide exchange
[3,41]. (ii) Domain I carries post-translational modifications such
as phosphorylations and single-, di- and tri-methylations that often
vary between species (reviewed by [7,16,42,43]). These differences
may affect the rate of binding of tRNA to ribosomes [6] or critical
protein-protein interactions with other factors involved in protein
synthesis such as translation elongation factor eEF1Balpha [3] or
factors interacting with eEF1A involved in other functions than
translation (reviewed in [4]). In a similar fashion, various (in)direct
binding partners of translation initiation factor eIF4A such as
eIF4G, p97, eIF4AIII and eIF4E have been reported to have
different binding properties when comparing mammalian to yeast
eIF4A [44,45,46,47]. In conclusion, the functional evolution of
translation factors such as eEF1A and eIF4A may be driven by
structural changes in protein partners rather than by changes in its
own amino acid sequence.
eEF1A Domain I Is Required for Complementation
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e42338
Supporting Information
Figure S1 ClustalW Multiple sequence alignment of
eEF1A sequences from different sources. Yellow indicates
conserved and semi-conserved substitutions within a column of
residues. Unconserved changes are black boxed. eEF1A domain I
is shown underlined in blue, domain II underlined in orange and
domain III underlined in red. Protein accession numbers for
eEF1A sequences: T. brucei, P86934; L. major, Q4QEI8; S. cerevisiae,
P50522; C. albicans, Q59K68; H. sapiens, P68104; A. thaliana,
P1390.
(DOC)
Table S1 Primers used for experiments with T. Brucei.
Table S1a. Primers for generation of constructs used for in vivo
complementation assay in T. brucei. Underlined nucleotides
indicate mutated triplets. Table S1b. Primers used in RT-PCR
method to detect specific eEF1A transcripts in T. brucei RNAi cell
line C5.
(DOC)
Table S2 Primers used for experiments with S. Cerevi-
siae. Table S2a. Primers used to produce ScEF1AHis6X and
amplification of eEF1A genes from different eukaryotic sources.
Underlined nucleotides indicate sequences of restriction sites,
letters in bold prints the His6x-tag sequence. Table S2b. Primers to
produce interspecies chimeric constructs. Underlined nucleotides
indicate sequences of restriction sites, letters in bold represent
mutagenized nucleotides.
(DOC)
Table S3 Plasmids used for experiments with S.
Cerevisiae.
(DOC)
Table S4 Genotype of yeast strains used in this work.
(DOC)
Acknowledgments
P.B. thanks the Bern University Research Foundation for support and A.
Atkins for valuable input. E.G. is grateful to P. Ma¨ser for support.
Author Contributions
Conceived and designed the experiments: SE EG PB MA. Performed the
experiments: SE EG MH. Analyzed the data: MH. Wrote the paper: PB
MA.
References
1. Sasikumar AN, Perez WB, Kinzy TG (2012) The many roles of the eukaryotic
elongation factor 1 complex. Wiley interdisciplinary reviews RNA.
2. Andersen GR, Nissen P, Nyborg J (2003) Elongation factors in protein
biosynthesis. Trends in biochemical sciences 28: 434–441.
3. Andersen GR, Valente L, Pedersen L, Kinzy TG, Nyborg J (2001) Crystal
structures of nucleotide exchange intermediates in the eEF1A-eEF1Balpha
complex. Nature structural biology 8: 531–534.
4. Mateyak MK, Kinzy TG (2010) eEF1A: thinking outside the ribosome. The
Journal of biological chemistry 285: 21209–21213.
5. Chang YW, Traugh JA (1998) Insulin stimulation of phosphorylation of
elongation factor 1 (eEF-1) enhances elongation activity. European journal of
biochemistry/FEBS 251: 201–207.
6. Peters HI, Chang YW, Traugh JA (1995) Phosphorylation of elongation factor 1
(EF-1) by protein kinase C stimulates GDP/GTP-exchange activity. European
journal of biochemistry/FEBS 234: 550–556.
7. Dever TE, Costello CE, Owens CL, Rosenberry TL, Merrick WC (1989)
Location of seven post-translational modifications in rabbit elongation factor 1
alpha including dimethyllysine, trimethyllysine, and glycerylphosphorylethano-
lamine. The Journal of biological chemistry 264: 20518–20525.
8. Fonzi WA, Katayama C, Leathers T, Sypherd PS (1985) Regulation of protein
synthesis factor EF-1 alpha in Mucor racemosus. Molecular and cellular biology
5: 1100–1103.
9. Zobel-Thropp P, Yang MC, Machado L, Clarke S (2000) A novel post-
translational modification of yeast elongation factor 1A. Methylesterification at
the C terminus. The Journal of biological chemistry 275: 37150–37158.
10. Ransom WD, Lao PC, Gage DA, Boss WF (1998) Phosphoglycerylethanolamine
posttranslational modification of plant eukaryotic elongation factor 1alpha. Plant
physiology 117: 949–960.
11. Rosenberry TL, Krall JA, Dever TE, Haas R, Louvard D, et al. (1989)
Biosynthetic incorporation of [3H]ethanolamine into protein synthesis elonga-
tion factor 1 alpha reveals a new post-translational protein modification. The
Journal of biological chemistry 264: 7096–7099.
12. Whiteheart SW, Shenbagamurthi P, Chen L, Cotter RJ, Hart GW (1989)
Murine elongation factor 1 alpha (EF-1 alpha) is posttranslationally modified by
novel amide-linked ethanolamine-phosphoglycerol moieties. Addition of etha-
nolamine-phosphoglycerol to specific glutamic acid residues on EF-1 alpha. The
Journal of biological chemistry 264: 14334–14341.
13. Signorell A, Jelk J, Rauch M, Bu¨tikofer P (2008) Phosphatidylethanolamine is
the precursor of the ethanolamine phosphoglycerol moiety bound to eukaryotic
elongation factor 1A. The Journal of biological chemistry 283: 20320–20329.
14. Greganova E, Altmann M, Bu¨tikofer P (2011) Unique modifications of
translation elongation factors. The FEBS journal 278: 2613–2624.
15. Greganova E, Heller M, Bu¨tikofer P (2010) A structural domain mediates
attachment of ethanolamine phosphoglycerol to eukaryotic elongation factor 1A
in Trypanosoma brucei. PloS one 5: e9486.
16. Cavallius J, Zoll W, Chakraburtty K, Merrick WC (1993) Characterization of
yeast EF-1 alpha: non-conservation of post-translational modifications. Biochi-
mica et biophysica acta 1163: 75–80.
17. Vassella E, Den Abbeele JV, Bu¨tikofer P, Renggli CK, Furger A, et al. (2000) A
major surface glycoprotein of trypanosoma brucei is expressed transiently during
development and can be regulated post-transcriptionally by glycerol or hypoxia.
Genes & development 14: 615–626.
18. Vassella E, Bu¨tikofer P, Engstler M, Jelk J, Roditi I (2003) Procyclin null mutants
of Trypanosoma brucei express free glycosylphosphatidylinositols on their
surface. Molecular biology of the cell 14: 1308–1318.
19. Vassella E, Boshart M (1996) High molecular mass agarose matrix supports
growth of bloodstream forms of pleomorphic Trypanosoma brucei strains in
axenic culture. Molecular and biochemical parasitology 82: 91–105.
20. Greganova E, Bu¨tikofer P (2012) Ethanolamine phosphoglycerol attachment to
eEF1A is not essential for normal growth of Trypanosoma brucei. Scientific
reports 2: 254.
21. Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible
expression system for conditional gene knock-outs and dominant-negative
genetics in Trypanosoma brucei. Molecular and biochemical parasitology 99:
89–101.
22. Beverley SM, Clayton CE (1993) Transfection of Leishmania and Trypanosoma
brucei by electroporation. Methods in molecular biology 21: 333–348.
23. Shi H, Djikeng A, Mark T, Wirtz E, Tschudi C, et al. (2000) Genetic
interference in Trypanosoma brucei by heritable and inducible double-stranded
RNA. RNA 6: 1069–1076.
24. Bu¨tikofer P, Ruepp S, Boschung M, Roditi I (1997) ‘GPEET’ procyclin is the
major surface protein of procyclic culture forms of Trypanosoma brucei brucei
strain 427. The Biochemical journal 326 (Pt 2): 415–423.
25. van Oostveen I, Ducret A, Aebersold R (1997) Colloidal silver staining of
electroblotted proteins for high sensitivity peptide mapping by liquid
chromatography-electrospray ionization tandem mass spectrometry. Analytical
biochemistry 247: 310–318.
26. Altmann M, Wittmer B, Methot N, Sonenberg N, Trachsel H (1995) The
Saccharomyces cerevisiae translation initiation factor Tif3 and its mammalian
homologue, eIF-4B, have RNA annealing activity. The EMBO journal 14:
3820–3827.
27. Bates PA, Kelley LA, MacCallum RM, Sternberg MJ (2001) Enhancement of
protein modeling by human intervention in applying the automatic programs
3D-JIGSAW and 3D-PSSM. Proteins Suppl 5: 39–46.
28. Bates PA, Sternberg MJ (1999) Model building by comparison at CASP3: using
expert knowledge and computer automation. Proteins Suppl 3: 47–54.
29. Contreras-Moreira B, Bates PA (2002) Domain fishing: a first step in protein
comparative modelling. Bioinformatics 18: 1141–1142.
30. Ozturk SB, Vishnu MR, Olarewaju O, Starita LM, Masison DC, et al. (2006)
Unique classes of mutations in the Saccharomyces cerevisiae G-protein
translation elongation factor 1A suppress the requirement for guanine nucleotide
exchange. Genetics 174: 651–663.
31. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A
‘‘silent’’ polymorphism in the MDR1 gene changes substrate specificity. Science
315: 525–528.
32. Altmann M, Muller PP, Pelletier J, Sonenberg N, Trachsel H (1989) A
mammalian translation initiation factor can substitute for its yeast homologue in
vivo. The Journal of biological chemistry 264: 12145–12147.
33. Yoffe Y, Zuberek J, Lerer A, Lewdorowicz M, Stepinski J, et al. (2006) Binding
specificities and potential roles of isoforms of eukaryotic initiation factor 4E in
Leishmania. Eukaryotic cell 5: 1969–1979.
eEF1A Domain I Is Required for Complementation
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e42338
34. Barhoumi M, Tanner NK, Banroques J, Linder P, Guizani I (2006) Leishmania
infantum LeIF protein is an ATP-dependent RNA helicase and an eIF4A-like
factor that inhibits translation in yeast. The FEBS journal 273: 5086–5100.
35. Prat A, Schmid SR, Buser P, Blum S, Trachsel H, et al. (1990) Expression of
translation initiation factor 4A from yeast and mouse in Saccharomyces
cerevisiae. Biochimica et biophysica acta 1050: 140–145.
36. Linder P, Lasko PF, Ashburner M, Leroy P, Nielsen PJ, et al. (1989) Birth of the
D-E-A-D box. Nature 337: 121–122.
37. de la Cruz J, Kressler D, Linder P (1999) Unwinding RNA in Saccharomyces
cerevisiae: DEAD-box proteins and related families. Trends in biochemical
sciences 24: 192–198.
38. Arcari P, Masullo M, Arcucci A, Ianniciello G, de Paola B, et al. (1999) A
chimeric elongation factor containing the putative guanine nucleotide binding
domain of archaeal EF-1 alpha and the M and C domains of eubacterial EF-Tu.
Biochemistry 38: 12288–12295.
39. Pape T, Wintermeyer W, Rodnina MV (1998) Complete kinetic mechanism of
elongation factor Tu-dependent binding of aminoacyl-tRNA to the A site of the
E. coli ribosome. The EMBO journal 17: 7490–7497.
40. Gromadski KB, Schummer T, Stromgaard A, Knudsen CR, Kinzy TG, et al.
(2007) Kinetics of the interactions between yeast elongation factors 1A and
1Balpha, guanine nucleotides, and aminoacyl-tRNA. The Journal of biological
chemistry 282: 35629–35637.
41. Andersen GR, Pedersen L, Valente L, Chatterjee I, Kinzy TG, et al. (2000)
Structural basis for nucleotide exchange and competition with tRNA in the yeast
elongation factor complex eEF1A:eEF1Balpha. Molecular cell 6: 1261–1266.
42. van Hemert FJ, Amons R, Pluijms WJ, van Ormondt H, Moller W (1984) The
primary structure of elongation factor EF-1 alpha from the brine shrimp
Artemia. The EMBO journal 3: 1109–1113.
43. Merrick WC (1992) Mechanism and regulation of eukaryotic protein synthesis.
Microbiological reviews 56: 291–315.
44. Levy-Strumpf N, Deiss LP, Berissi H, Kimchi A (1997) DAP-5, a novel homolog
of eukaryotic translation initiation factor 4G isolated as a putative modulator of
gamma interferon-induced programmed cell death. Molecular and cellular
biology 17: 1615–1625.
45. Imataka H, Olsen HS, Sonenberg N (1997) A new translational regulator with
homology to eukaryotic translation initiation factor 4G. The EMBO journal 16:
817–825.
46. Li Q, Imataka H, Morino S, Rogers GW, Jr., Richter-Cook NJ, et al. (1999)
Eukaryotic translation initiation factor 4AIII (eIF4AIII) is functionally distinct
from eIF4AI and eIF4AII. Molecular and cellular biology 19: 7336–7346.
47. Yamanaka S, Poksay KS, Arnold KS, Innerarity TL (1997) A novel translational
repressor mRNA is edited extensively in livers containing tumors caused by the
transgene expression of the apoB mRNA-editing enzyme. Genes & development
11: 321–333.
eEF1A Domain I Is Required for Complementation
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e42338
